BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30601533)

  • 41. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
    Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
    ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
    Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
    Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
    Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
    Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
    Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
    Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
    Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of Novel Methyl 3-(hetero)arylthieno[3,2-
    Silva BR; Rebelo R; Rodrigues JM; Xavier CPR; Vasconcelos MH; Queiroz MRP
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33805741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
    Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.
    Bachmann AS; Opoku-Ansah J; Ibarra-Rivera TR; Yco LP; Ambadi S; Roberts CC; Chang CE; Pirrung MC
    J Biol Chem; 2016 Apr; 291(16):8350-62. PubMed ID: 26907687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 54. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
    Momose I; Abe H; Watanabe T; Ohba S; Yamazaki K; Dan S; Yamori T; Masuda T; Nomoto A
    Cancer Sci; 2014 Dec; 105(12):1609-15. PubMed ID: 25251038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer.
    Liu G; Yin T; Kim H; Ding C; Yu Z; Wang H; Chen H; Yan R; Wold EA; Zou H; Liu X; Ding Y; Shen Q; Zhou J
    Eur J Med Chem; 2019 Sep; 178():589-605. PubMed ID: 31220676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
    J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
    Lin Y; Liu R; Zhao P; Ye J; Zheng Z; Huang J; Zhang Y; Gao Y; Chen H; Liu S; Zhou J; Chen C; Chen H
    Eur J Med Chem; 2018 Feb; 146():354-367. PubMed ID: 29407962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.